Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, May 10, 2021
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
[ Mon, May 10th 2021
] - WOPRAI
Matthew Harrison Maintained (ADCT) at Buy with Decreased Target to $53 on, May 10th, 2021
Matthew Harrison of Morgan Stanley, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $55 to $53 on, May 10th, 2021.
Matthew has made no other calls on ADCT in the last 4 months.
There is 1 other peer that has a rating on ADCT. Out of the 1 peers that are also analyzing ADCT, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $57 on, Monday, April 26th, 2021
